Targeting of Liposomes to Solid Tumors: The Case of Sterically Stabilized Anti-Her2 Immunoliposomes

AbstractNovel therapies for cancer call for a carrier capable of intracellular delivery of systemically administered drugs to cancer cells in solid tumors. Such carrier, sterically stabilized immunoliposomes specific to the cells expressing HER2 protooncogene (anti-HER2 SSL), was designed by conjugating Fab' fragments of a recombinant humanized anti-HER2 MAb to the distal termini of poly(ethylene glycol) chains on the surface of unilamellar liposomes (size 90-100 nm) of phosphatidylcholine, cholesterol, and poly(ethylene glycol)-derivatized phosphatidylethanolamine. Anti-HER2 SSL avidly and specifically bound to cultured HER2-overexpressing cancer cells (8,000-23,000 vesicles per cell) and became endocytosed (ke=0.022–0.033 min.-1) via the coated pit pathway. Anti-HER2 SSL showed prolonged circulation lifetime in rats (blood MRT approx. 24 hours) and significantly increased antitumor activity of encapsulated doxorubicin against HER2-overexpressing human breast cancer xenografts in nude mice. Although the ...

[1]  C. Benz,et al.  Anti-HER2 immunoliposomes for targeted therapy of human tumors. , 1997, Cancer letters.

[2]  John W. Park,et al.  Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. , 1997, Biochemistry.

[3]  John W. Park,et al.  Immunoliposomes for cancer treatment. , 1997, Advances in pharmacology.

[4]  Y. Yarden,et al.  Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. , 1996, British Journal of Cancer.

[5]  G. Adams,et al.  Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. , 1996, Journal of molecular biology.

[6]  T. Allen,et al.  Long-circulating, polyethylene glycol-grafted immunoliposomes , 1996 .

[7]  D Tripathy,et al.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Mes-Masson,et al.  Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. , 1996, Cancer letters.

[9]  E. Moase,et al.  Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. , 1995, Biochimica et biophysica acta.

[10]  J. Silvius,et al.  A novel strategy affords high-yield coupling of antibody Fab' fragments to liposomes. , 1995, Biochimica et biophysica acta.

[11]  T. Masuko,et al.  Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on human cancer cells. , 1995, British Journal of Cancer.

[12]  T. Allen,et al.  A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. , 1995, Biochimica et biophysica acta.

[13]  T. McIntosh,et al.  Structure and phase behavior of lipid suspensions containing phospholipids with covalently attached poly(ethylene glycol). , 1995, Biophysical journal.

[14]  J. Huston,et al.  In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. , 1995, Immunotechnology : an international journal of immunological engineering.

[15]  Y. Yarden,et al.  Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  L. Huang,et al.  Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. , 1995, Biochimica et biophysica acta.

[17]  John W. Park,et al.  Development of anti-p185HER2 immunoliposomes for cancer therapy. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[18]  B. Nakata,et al.  Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival , 1995, International journal of pancreatology : official journal of the International Association of Pancreatology.

[19]  D. Papahadjopoulos.  30-Year Progress for Liposomes: From Serendipity to Molecular Design , 1995 .

[20]  N. Hynes,et al.  The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.

[21]  L. Cantley,et al.  A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling , 1994, Cell.

[22]  M. Newman,et al.  Pharmacokinetics, Biodistribution and Therapeutic Efficacy of Doxorubicin Encapsulated in Stealth® Liposomes (Doxil®) , 1994 .

[23]  Y. Barenholz,et al.  Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.

[24]  T. Singleton,et al.  Stability of HER-2/neu expression over time and at multiple metastatic sites. , 1993, Journal of the National Cancer Institute.

[25]  G. Storm,et al.  Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. , 1993, Biochimica et biophysica acta.

[26]  D. Papahadjopoulos,et al.  Quantitative analysis of liposome-cell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. , 1993, Biochemistry.

[27]  F. Martin,et al.  Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. , 1992, Cancer research.

[28]  D. Friend,et al.  Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. , 1992, Cancer research.

[29]  V. Torchilin,et al.  Targeted accumulation of polyethylene glycol‐coated immunoliposomes in infarcted rabbit myocardium , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[31]  B. Ljung,et al.  The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. , 1992, Oncogene.

[32]  P. Carter,et al.  Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. , 1992, Cancer treatment and research.

[33]  A. Gabizon,et al.  Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Heitjan.  Generalized Norton-Simon models of tumour growth. , 1991, Statistics in medicine.

[35]  V. Torchilin,et al.  Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo , 1991, FEBS letters.

[36]  A. Ullrich,et al.  Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. , 1991, Growth regulation.

[37]  M. Campiglio,et al.  Selection of monoclonal antibodies which induce internalization and phosphorylation of P185HER2 and growth inhibition of cells with HER2/neu gene amplification , 1991, International journal of cancer.

[38]  V. Torchilin,et al.  Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. , 1991, Biochimica et biophysica acta.

[39]  R. Bast,et al.  Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. , 1991 .

[40]  G Blume,et al.  Liposomes for the sustained drug release in vivo. , 1990, Biochimica et biophysica acta.

[41]  M. Bally,et al.  Optimized procedures for the coupling of proteins to liposomes. , 1990, JIM - Journal of Immunological Methods.

[42]  D. Weiner,et al.  p185neu expression in human lung adenocarcinomas predicts shortened survival. , 1990, Cancer research.

[43]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[44]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.

[45]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[46]  D. Papahadjopoulos,et al.  Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay. , 1990, Biochimica et biophysica acta.

[47]  M. Bally,et al.  The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. , 1990, Chemistry and physics of lipids.

[48]  A. Ullrich,et al.  Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. , 1990, Cancer research.

[49]  M. Hung,et al.  Amplification and expression of the c‐erb B‐2/neu proto‐oncogene in human bladder cancer , 1990, Molecular carcinogenesis.

[50]  J. Rhim,et al.  Amplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas. , 1989, Cancer research.

[51]  V. Ranade.  Drug Delivery Systems. 1. Site‐Specific Drug Delivery Using Liposomes as Carriers , 1989, Journal of clinical pharmacology.

[52]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[53]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[54]  D. Papahadjopoulos,et al.  Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes. , 1988, Cancer research.

[55]  A. Gabizon,et al.  Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[56]  N. Nomura,et al.  Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. , 1988, Oncogene.

[57]  A. Gabizon,et al.  An Improved Method for in Vivo Tracing and Imaging of Liposomes Using a Gallium 67-Deferoxamine Complex , 1988 .

[58]  T M Allen,et al.  Large unilamellar liposomes with low uptake into the reticuloendothelial system , 1987, FEBS letters.

[59]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[60]  F. Ligler,et al.  Effect of covalent attachment of immunoglobulin fragments on liposomal integrity. , 1986, Biochemistry.

[61]  D. Friend,et al.  Liposomes containing colloidal gold are a useful probe of liposome-cell interactions. , 1983, Biochimica et biophysica acta.

[62]  F. Martin,et al.  Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting. , 1982, The Journal of biological chemistry.

[63]  R. Nezlin.  Structure and biosynthesis of antibodies , 1980 .

[64]  F. Szoka,et al.  Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. , 1979, Biochimica et biophysica acta.

[65]  K. Jacobson,et al.  Phase transitions in phospholipid vesicles. Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. , 1973, Biochimica et biophysica acta.